Baby formula production resumes at Abbott Nutrition factory in Michigan
"We are working to restart Similac production as soon as we can. We'll provide more information when we have it," Abbott spokesman John Koval said via email.
Michigan: Production of baby formula has resumed at the Abbott Nutrition factory in Michigan whose February shutdown over contamination contributed to a national shortage, a company spokesman said. Damage from severe thunderstorms including flooding had forced the Sturgis plant to halt operations in mid-June just two weeks after restarting production with additional sanitizing and safety protocols.
Production of EleCare, a specialty formula for infants with severe food allergies and digestive problems, was restored at Sturgis following a July 1 reboot, said Abbott spokesman John Koval.
"We are working to restart Similac production as soon as we can. We'll provide more information when we have it," he said via email.
Abbott recalled several leading brands of formula in February, including Similac. That squeezed supplies already been strained by supply chain disruptions and stockpiling during COVID-19 shutdowns.
The shortage was most dire for children with allergies, digestive problems and metabolic disorders who rely on specialty formulas.
President Joe Biden's administration has since eased import rules for foreign manufacturers, airlifted formula from Europe and invoked federal emergency rules to prioritize U.S. production.
Abbott is one of just four companies that produce about 90% of U.S. formula. Koval declined to say how much of Abbot's overall U.S. supply of infant formula is produced at the Sturgis plant.
The plant was closed in February after the Food and Drug Administration began investigating four bacterial infections among infants who consumed powdered formula from the plant. Two of the babies died. The company says its products have not been directly linked to the infections, which involved different bacterial strains.
FDA inspectors eventually uncovered a host of violations at the plant, including bacterial contamination, a leaky roof and lax safety protocols.
On Wednesday, the Food and Drug Administration announced plans to help overseas makers of infant formula that have sent supplies, under emergency approval to address the shortfall, secure long-term authorization to market their formula in the U.S. The plan is to provide American consumers with more choices and make supplies more resilient against current or future shortages
FDA commissioner, Dr. Robert Califf, and Susan Mayne, the director of the agency's Center for Food Safety and Applied Nutrition, said in a statement that the Sturgis plant shutdown "compounded by unforeseen natural weather events, has shown just how vulnerable the supply chain has become."
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.